Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.76 |
| ▸ | THRB | P10828 | 14/20 | 0.42 |
| ▸ | THRA | P10827 | 12/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631238 | 0.93 | NR3C1 (0.81) | NR3C1THRBTHRASMN1; SMN2 | |
| SCHEMBL5632870 | 0.92 | NR3C1 (0.81) | NR3C1THRBTHRASMN1; SMN2 | |
| SCHEMBL5632284 | 0.91 | NR3C1 (0.77) | NR3C1THRBTHRAMEN1KMT2A | |
| SCHEMBL5631254 | 0.90 | NR3C1 (0.76) | NR3C1THRBTHRAMEN1KMT2A | |
| SCHEMBL5631912 | 0.89 | NR3C1 (0.85) | NR3C1THRBTHRA | |
| SCHEMBL5632313 | 0.89 | NR3C1 (0.76) | NR3C1THRBTHRAMEN1KMT2A | |
| SCHEMBL14514541 | 0.89 | NR3C1 (0.73) | NR3C1THRBTHRAMEN1KMT2A | |
| SCHEMBL5630785 | 0.89 | NR3C1 (0.76) | NR3C1THRBTHRAMEN1KMT2A | |
| SCHEMBL5634096 | 0.88 | NR3C1 (0.75) | NR3C1THRBTHRA | |
| SCHEMBL7250408 | 0.88 | NR3C1 (0.82) | NR3C1THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220752-B2 | Compounds active at the glucocorticoid receptor II | KARO BIO AB (SE) | 2007-05-22 | — | — | US | claimed |
| EP-1509188-A4 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR II | KAROBIO AB (SE) | 2005-11-23 | — | — | EP | claimed |
| EP-1509188-A2 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR II | KARO BIO AB (SE) | 2005-03-02 | — | — | EP | claimed |
| US-20040063781-A1 | Compounds active at the glucocorticoid receptor II | ABBOTT LABORATORIES | 2004-04-01 | — | — | US | claimed |
| WO-2002043648-A2 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR II | KARO BIO AB (SE) | 2002-06-06 | — | — | WO | claimed |
| US-7220752-B2 | Compounds active at the glucocorticoid receptor II | KARO BIO AB (SE) | 2007-05-22 | — | — | US | disclosed |
| US-7220752-B2 | Compounds active at the glucocorticoid receptor II | KARO BIO AB (SE) | 2007-05-22 | — | — | US | disclosed |
| US-7220752-B2 | Compounds active at the glucocorticoid receptor II | KARO BIO AB (SE) | 2007-05-22 | — | — | US | disclosed |
| EP-1509188-A4 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR II | KAROBIO AB (SE) | 2005-11-23 | — | — | EP | disclosed |
| EP-1509188-A2 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR II | KARO BIO AB (SE) | 2005-03-02 | — | — | EP | disclosed |
| US-20040063781-A1 | Compounds active at the glucocorticoid receptor II | ABBOTT LABORATORIES | 2004-04-01 | — | — | US | disclosed |
| WO-2002043648-A2 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR II | KARO BIO AB (SE) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063781-A1 | Compounds active at the glucocorticoid receptor II | NR3C1, MC2R, NR3C2 | NR3C1 1/4885THRB 219/4885THRA 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.